Clinical trial Recruiting at 1 site Observational Ages 18 and up

GLP-1 receptor agonists and dry eye in adults with type 2 diabetes and obesity

Official title: Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity

Run by Attikon Hospital · NCT07605572 · Data updated 2026-11-12

This study tests whether GLP-1 receptor agonists affect dry eye disease in adults with type 2 diabetes and obesity.

More GLP-1 trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorAttikon Hospital
Academic / other
Locations1 site (Athens)
StatusRecruiting
StartedMarch 1, 2026
Main results expectedDecember 31, 2026
Study endsFebruary 28, 2027
Registry record updatedJune 2, 2026
Trial IDNCT07605572 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with type 2 diabetes and obesity who have not previously used GLP-1 receptor agonists and can provide informed consent.

Probably not a fit

Patients with active intraocular inflammation, recent eye surgery, or conditions listed in the exclusion criteria may not experience benefit related to dry eye outcomes.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort follows adults with type 2 diabetes and obesity to see how GLP-1 receptor agonists relate to the presence and severity of dry eye disease. The study is prospective and does not specify an interventional protocol. Researchers will compare ocular surface outcomes before and after exposure to GLP-1 receptor agonists in eligible participants, while accounting for relevant ocular and systemic factors. Inclusion requires adults 18 or older who have not previously used GLP-1 receptor agonists, with informed consent. Exclusion criteria include pregnancy, significant hypoglycemia history, active intraocular inflammation, recent eye surgery, ketoacidosis history, and corneal transplant history. Lead sponsorship is from Attikon Hospital, with collaboration at a center in Athens, Greece.

Why it matters

Potential benefit: If GLP-1 receptor agonists influence ocular surface biology, this could inform personalized treatment considerations for dry eye in patients with diabetes and obesity.

How similar studies have gone: Previous research has documented links between diabetes, obesity, and dry eye, and this study explores a novel angle by examining GLP-1 receptor agonists’ association with ocular surface outcomes.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥18 years.
2. Patients who have not previously received GLP-1 receptor agonists (GLP-1 RAs).
3. Patients able to provide informed consent for participation in the study.

Exclusion Criteria:

1. Pregnant or breastfeeding patients.
2. History of multiple severe hypoglycemic episodes within the past two years.
3. Active intraocular inflammation in either eye, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis.
4. Patients who have undergone cataract surgery or vitrectomy within the past 6 months.
5. History of ketoacidosis or metabolic acidosis.
6. History of corneal transplantation.

Where it's running

  • 2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, Athens, GRC.
    Athens, Greece
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.